赛诺菲安万特2026年初面临高管变动与业绩增长挑战

Group 1 - The company is undergoing a significant leadership change with CEO Paul Hudson announcing his departure in February 2026, to be succeeded by Beren Garijo in April 2026, which may impact the company's strategic direction and R&D efficiency [2] - The company expects a high single-digit percentage growth in sales for 2026, with earnings per share growth slightly exceeding sales growth, and plans to execute a €1 billion stock buyback program [3] - The company faces critical R&D challenges and needs to accelerate its drug pipeline to replace its core product Dupixent, which accounts for over 30% of revenue and has a patent expiring in the early 2030s, while its vaccine business may continue to be pressured by U.S. policies [4]